PRAX Stock Price
Praxis Precision Medicines, Inc.
PRAX stock price is $241.76 (-2.61% on the day), giving Praxis Precision Medicines, Inc. a market cap of $6.75B. Below are the price chart, the MarketXLS Rank, the company profile and the latest news.
PRAX Stock Overview
- Price
- $241.76
- Previous close
- $248.24
- Open
- $250.11
- Market cap
- $6.75B
- P/E ratio
- -22.3
- 52-week range
- $154.45 - $392.70
- 1-year price target
- $637.68
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NGS
- MarketXLS Rank
- 31
About Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. The company offers cerebrum, a small molecule platform for CNS small molecule therapies and solidus, an antisense oligonucleotide platform to discover and develop antisense oligonucleotide. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain to treat focal onset epilepsy; relutrigine for the treatment of developmental and epileptic encephalopathies; PRAX-020; and PRAX-050. In addition, the company develops elsunersen, a clinical-stage ASO designed to regulate NaV1.2 expression for the treatment of SCN2A-DEE; PRAX-080; PRAX-090; and PRAX-100. It has a license agreement with RogCon Inc.; and research collaboration and license agreement with Ionis Pharmaceuticals, Inc. The company was incorporated in 2015 and is based in Boston, Massachusetts.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PRAX | $241.76 | -2.6% | 541.79K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Praxis Precision Medicines, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW